Uric acid sodium

Powder: -20 degree C for 3 years | In solvent: -80 degree C for 1 year

190.09

[Na+].[O-]c1nc2c([nH]1)[nH]c(=O)[nH]c2=O

C5H3N4NaO3

DMSO: 2.8 mg/mL (14.8 mM)
ultrasonic and warming and adjust pH to 4 with HCl and heat to 60 degree C
(< 1 mg/ml refers to the product slightly soluble or insoluble)

1198-77-2

Uric acid, when administered at a concentration of 400uM for 48 hours, offers protection to Caco-2 cells by preventing indomethacin-induced lipid peroxidation [2]. Furthermore, co-treatment of cells with indomethacin and uric acid sodium (200uM indomethacin plus 400uM uric acid; 24 hours) significantly reduces reactive oxygen species (ROS) levels compared to cells treated with indomethacin alone. Additionally, cell viability in Caco-2 cells exposed to both indomethacin and uric acid sodium (200uM indomethacin plus 400uM uric acid; 24 hours) is higher compared to cells treated solely with indomethacin. The protective effect of uric acid sodium on indomethacin-induced changes in intestinal cells is attributed to its antioxidant activity.

Oral treatment of uric acid sodium at a dosage of 250 mg/kg has a beneficial effect on indomethacin-induced enteropathy. It ameliorates the enteropathy caused by indomethacin. Oral treatment of uric acid sodium leads to a reduction in ROS accumulation in the ileum in a mouse model of indomethacin-induced enteropathy [2].